vs
百特国际（BAX）与阿特斯（CSIQ）财务数据对比。点击上方公司名可切换其他公司
阿特斯的季度营收约是百特国际的1.5倍（$4.5B vs $3.0B），阿特斯净利率更高（1.3% vs -37.9%，领先39.2%）
百特国际是总部位于美国伊利诺伊州迪尔菲尔德的跨国医疗健康企业，业务布局覆盖全球众多市场，专注于研发、生产及销售各类医疗相关产品与解决方案，为全球医疗机构和患者提供专业可靠的医疗支持。
阿特斯是全球领先的可再生能源企业，总部位于加拿大安大略省基奇纳。核心业务涵盖光伏组件制造、电池储能解决方案供应，以及大型公用事业级太阳能电站与储能项目的开发，业务布局覆盖全球主要能源市场。
BAX vs CSIQ — 直观对比
营收规模更大
CSIQ
是对方的1.5倍
$3.0B
净利率更高
CSIQ
高出39.2%
-37.9%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $3.0B | $4.5B |
| 净利润 | $-1.1B | $57.6M |
| 毛利率 | 19.4% | 17.5% |
| 营业利润率 | -24.5% | 2.2% |
| 净利率 | -37.9% | 1.3% |
| 营收同比 | 458.0% | — |
| 净利润同比 | -120.3% | — |
| 每股收益（稀释后） | $-2.21 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BAXCSIQ
| Q4 25 | $3.0B | — | ||
| Q3 25 | $2.8B | $4.5B | ||
| Q2 25 | $2.8B | $3.0B | ||
| Q1 25 | $2.6B | $1.3B | ||
| Q4 24 | $533.0M | — | ||
| Q3 24 | $2.7B | $5.9B | ||
| Q2 24 | $3.8B | $4.1B | ||
| Q1 24 | $3.6B | — |
净利润BAXCSIQ
| Q4 25 | $-1.1B | — | ||
| Q3 25 | $-46.0M | $57.6M | ||
| Q2 25 | $91.0M | $63.6M | ||
| Q1 25 | $126.0M | $36.2M | ||
| Q4 24 | $-512.0M | — | ||
| Q3 24 | $140.0M | $366.8M | ||
| Q2 24 | $-314.0M | $304.4M | ||
| Q1 24 | $37.0M | — |
毛利率BAXCSIQ
| Q4 25 | 19.4% | — | ||
| Q3 25 | 33.5% | 17.5% | ||
| Q2 25 | 35.3% | 18.0% | ||
| Q1 25 | 32.8% | 19.0% | ||
| Q4 24 | 25.0% | — | ||
| Q3 24 | 38.3% | 18.0% | ||
| Q2 24 | 37.5% | 18.7% | ||
| Q1 24 | 38.6% | — |
营业利润率BAXCSIQ
| Q4 25 | -24.5% | — | ||
| Q3 25 | 6.1% | 2.2% | ||
| Q2 25 | 6.8% | 3.3% | ||
| Q1 25 | 2.2% | 3.7% | ||
| Q4 24 | -25.5% | — | ||
| Q3 24 | 5.7% | 7.7% | ||
| Q2 24 | -5.0% | 9.1% | ||
| Q1 24 | 5.2% | — |
净利率BAXCSIQ
| Q4 25 | -37.9% | — | ||
| Q3 25 | -1.6% | 1.3% | ||
| Q2 25 | 3.2% | 2.1% | ||
| Q1 25 | 4.8% | 2.7% | ||
| Q4 24 | -96.1% | — | ||
| Q3 24 | 5.2% | 6.2% | ||
| Q2 24 | -8.2% | 7.5% | ||
| Q1 24 | 1.0% | — |
每股收益（稀释后）BAXCSIQ
| Q4 25 | $-2.21 | — | ||
| Q3 25 | $-0.09 | — | ||
| Q2 25 | $0.18 | — | ||
| Q1 25 | $0.25 | — | ||
| Q4 24 | $-0.99 | — | ||
| Q3 24 | $0.27 | — | ||
| Q2 24 | $-0.62 | — | ||
| Q1 24 | $0.07 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.0B | $1.7B |
| 总债务越低越好 | $9.5B | — |
| 股东权益账面价值 | $6.1B | $3.9B |
| 总资产 | $20.1B | $13.5B |
| 负债/权益比越低杠杆越低 | 1.55× | — |
8季度趋势，按日历期对齐
现金及短期投资BAXCSIQ
| Q4 25 | $2.0B | — | ||
| Q3 25 | $1.7B | $1.7B | ||
| Q2 25 | $1.7B | $1.7B | ||
| Q1 25 | $2.3B | $1.7B | ||
| Q4 24 | $1.8B | — | ||
| Q3 24 | $1.4B | $1.9B | ||
| Q2 24 | $2.1B | $1.9B | ||
| Q1 24 | $3.0B | — |
总债务BAXCSIQ
| Q4 25 | $9.5B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $10.4B | — | ||
| Q3 24 | $10.4B | — | ||
| Q2 24 | $10.4B | — | ||
| Q1 24 | $11.1B | — |
股东权益BAXCSIQ
| Q4 25 | $6.1B | — | ||
| Q3 25 | $7.2B | $3.9B | ||
| Q2 25 | $7.3B | $3.9B | ||
| Q1 25 | $7.1B | $3.9B | ||
| Q4 24 | $7.0B | — | ||
| Q3 24 | $7.9B | $3.7B | ||
| Q2 24 | $7.6B | $3.7B | ||
| Q1 24 | $8.2B | — |
总资产BAXCSIQ
| Q4 25 | $20.1B | — | ||
| Q3 25 | $21.1B | $13.5B | ||
| Q2 25 | $21.0B | $13.5B | ||
| Q1 25 | $21.3B | $13.5B | ||
| Q4 24 | $25.8B | — | ||
| Q3 24 | $26.7B | $11.9B | ||
| Q2 24 | $26.3B | $11.9B | ||
| Q1 24 | $27.8B | — |
负债/权益比BAXCSIQ
| Q4 25 | 1.55× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.49× | — | ||
| Q3 24 | 1.33× | — | ||
| Q2 24 | 1.37× | — | ||
| Q1 24 | 1.36× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $584.0M | $-187.7M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | -3.26× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流BAXCSIQ
| Q4 25 | $584.0M | — | ||
| Q3 25 | $237.0M | $-187.7M | ||
| Q2 25 | $217.0M | — | ||
| Q1 25 | $-193.0M | — | ||
| Q4 24 | $488.0M | — | ||
| Q3 24 | $253.0M | — | ||
| Q2 24 | $115.0M | — | ||
| Q1 24 | $163.0M | — |
现金转化率BAXCSIQ
| Q4 25 | — | — | ||
| Q3 25 | — | -3.26× | ||
| Q2 25 | 2.38× | — | ||
| Q1 25 | -1.53× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 4.41× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BAX
| Other | $1.5B | 51% |
| Infusion Therapies And Technologies | $543.0M | 18% |
| Pharmaceutical Compounding | $316.0M | 11% |
| Front Line Care | $219.0M | 7% |
| Injectables And Anesthesia | $190.0M | 6% |
| Advanced Surgery | $177.0M | 6% |
CSIQ
暂无分部数据
